Method for assessing the efficacy of IMiDs and composition or combination for use in treating IMiD sensitive diseases

摘要

The invention relates to a combination of an immunomodulatory imide drug (IMID) and an inhibitor of CD147 and/or an inhibitor of MCT1 for use in treating a disease in a subject. It further relates to an inhibitor of CD147 and/or an inhibitor of MCT1 for use in treating a disease in a patient, wherein the patient is IMID resistant. It further relates to a method of monitoring the efficacy of an IMiD treatment regimen by comparing the protein level of CD147 and/or MCT1 in samples obtained from a subject prior and during IMiD treatment.